Oxlumo (Lumasiran)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Oxlumo (Lumasiran) is a medication used to treat primary hyperoxaluria type 1 (PH1), a rare genetic disorder. Lumasiran acts by targeting and silencing the HAO1 gene mRNA, leading to a decrease in the production of the glycolate oxidase (GO) enzyme and reducing oxalate overproduction. It is a double-stranded small interfering ribonucleic acid (siRNA) and falls under the category of RNAi therapeutics. Healthcare providers prescribe Oxlumo as a subcutaneous injection to decrease oxalate levels in urine and blood, aiding in preventing kidney damage and other complications linked to PH1.
Directions
Oxlumo is typically administered as a subcutaneous injection, meaning the injection is given under the skin. The standard Oxlumo dosing schedule depends on the patient's body weight. Typically, patients will receive a higher loading dose at the beginning of treatment, followed by maintenance doses at a lesser frequency.
It's important that patients follow their healthcare provider's instructions on when and how to inject Oxlumo. They should also be aware that Oxlumo may cause side effects such as injection site reactions, and they should contact their healthcare provider if they have concerns or experience unusual symptoms.
Ingredients
Lumasiran Sodium is the main active ingredient in Oxlumo.
Contraindications
The drug label for Oxlumo does not contain any contraindications. However, individuals with a known hypersensitivity to Lumasiran or any of its components should avoid taking the medication.
Cautions
- Before using Oxlumo, ensure you provide your healthcare provider with the following information:
- Existing health conditions
- Known allergies
- A list of all the medications you are currently taking
- Your pregnancy or breastfeeding status
- Before using, check Oxlumo to ensure the solution is clear, colorless-to-yellow, and free from particles. Do not use it if it appears cloudy, discolored, or contains particles.
- Always use aseptic techniques to prevent contamination when administering Oxlumo.
- The effects of Oxlumo during pregnancy are not well understood. There is no human data available, but animal studies did not show harmful effects at high doses.
- It is unknown if Oxlumo passes into human breast milk or if it affects milk production. The benefits of breastfeeding should be considered along with the mother’s need for Oxlumo.
- Oxlumo is approved for use in pediatric patients from birth onwards, supported by clinical studies in children and adults, including those with advanced kidney disease.
Side Effects
The long-term data suggest that Oxlumo is well-tolerated over extended periods. Oxlumo's most frequently reported side effects involve reactions at the injection site, such as redness, swelling, pain, and itching. These are generally mild and tend to resolve quickly. Stomach pain of varying types has also been noted but occurs less frequently.
References:
- Oxlumo (Lumasiran) Product Monograph. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2023.
- Oxlumo (Lumasiran) Drug Label Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 13769
- Before using Oxlumo, ensure you provide your healthcare provider with the following information:
-
Product Reviews
